(:MYOK)

Nov 15, 2020 04:30 pm ET
MyoKardia Presents Cardiac Imaging Data from 30-Week EXPLORER-HCM Study of Mavacamten
MyoKardia, Inc. (Nasdaq: MYOK) announced results from its cardiac magnetic resonance imaging (CMR) substudy of mavacamten for the potential treatment of hypertrophic cardiomyopathy (HCM) showing that 30-week treatment with mavacamten has a...
Nov 13, 2020 10:00 am ET
MyoKardia Presents Mavacamten Clinical and Non-Clinical Data at the American Heart Association’s Scientific Sessions 2020
MyoKardia, Inc. (Nasdaq: MYOK) today presented clinical and non-clinical data related to mavacamten, MyoKardia’s investigative therapeutic in late-stage development for the potential treatment of hypertrophic cardiomyopathy (HCM), at the American...
Nov 11, 2020 08:30 am ET
MyoKardia Collaborates with the American College of Cardiology and PINNACLE/Veradigm to Launch Patient Registry of Hypertrophic Cardiomyopathy
MyoKardia, Inc. (NASDAQ: MYOK), and the American College of Cardiology (ACC) announced the establishment of a nationwide registry of hypertrophic cardiomyopathy (HCM), which leverages the ACC’s PINNACLE Cardiovascular Registry operated by...
Nov 05, 2020 04:13 pm ET
MyoKardia Reports Third Quarter 2020 Financial Results
MyoKardia, Inc. (Nasdaq: MYOK) today reported financial results for the third quarter ended September 30, 2020. Recent Clinical Program Highlights Mavacamten for Hypertrophic Cardiomyopathy (HCM) EXPLORER-HCM Data Presented at the European...
Nov 04, 2020 08:30 am ET
MyoKardia Announces Awardees of the Second Annual MyoSeeds™ Research Grants Program
MyoKardia, Inc. (Nasdaq: MYOK) today announced three awardees of the 2020 MyoSeeds™ Research Grant Program, who have been selected to receive $250,000 each in support of original, independent research in the biology and underlying mechanisms of...
Nov 04, 2020 06:59 am ET
Bristol Myers Squibb and MyoKardia Announce Expiration of HSR Act Waiting Period
Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (Nasdaq: MYOK) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, in connection with Bristol Myers Squibb’s previously announced tender offer to acquire all outstanding shares of MyoKardia for a purchase price of $225.00 per share in cash, or approximately $13.1 billion. The expiration of the waiting period occurred at 11:59 p.m. EST on November 3, 2020.
Nov 02, 2020 08:30 am ET
MyoKardia Announces Multiple Abstracts Selected for Presentation at the Upcoming American Heart Association’s Annual Scientific Sessions 2020
MyoKardia, Inc. (Nasdaq: MYOK) today announced the upcoming presentation of clinical and non-clinical data related to mavacamten, MyoKardia’s investigative therapeutic in late-stage development for the potential treatment of hypertrophic...
Oct 31, 2020 07:15 pm ET
ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Merger Investigations; Investors are Encouraged to Contact the Firm - MR, MYOK, CBLI, SBPH, PTI, PRCP
NEW YORK, Oct. 31, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating:
Oct 21, 2020 04:16 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of CXO, BSTC, MYOK, and CBMG Mergers
Rigrodsky & Long, P.A. announces that it is investigating: Concho Resources Inc. (NYSE: CXO) regarding possible breaches of fiduciary duties and other violations of law related to Concho Resources’ agreement to be acquired by ConocoPhillips. Under...
Oct 21, 2020 11:46 am ET
Moore Kuehn Encourages MYOK, BSTC, CIT, and PE and Investors to Contact Law Firm
Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may ultimately seek...
Oct 20, 2020 03:12 pm ET
SHAREHOLDER ALERT: Halper Sadeh LLP is Investigating the Following Companies; Investors are Encouraged to Contact the Firm - MYOK, EIDX, CBMG
NEW YORK, Oct. 20, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating:
Oct 19, 2020 03:14 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of MYOK, CBMG, CIT, and STND Mergers
Rigrodsky & Long, P.A. announces that it is investigating: MyoKardia, Inc. (NASDAQ GS: MYOK) regarding possible breaches of fiduciary duties and other violations of law related to MyoKardia’s agreement to be acquired by Bristol-Myers Squibb...
Oct 15, 2020 12:14 pm ET
Lifshitz Law Firm, P.C. Announces Investigation of Montage Resources Corporation (NYSE: MR), MyoKardia, Inc. (NASDAQ: MYOK), Standard AVB Financial Corp. (NASDAQ GS: STND), and Virtusa Corporation (NA
Montage Resources Corporation (NYSE: MR) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of MR to Southwestern Energy Company. If you are a MR investor, and would like...
Oct 09, 2020 02:24 pm ET
MYOKARDIA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of MyoKardia, Inc. - MYOK
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of MyoKardia, Inc. (NasdaqGS: MYOK) to Bristol Myers Squibb (NYSE: BMY). Under the terms of the proposed transaction, shareholders of MyoKardia will receive only $225.00 in cash for each share of MyoKardia that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Oct 09, 2020 10:50 am ET
MERGER ALERT - ARA, MYOK, and SRAC: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
NEW YORK, NY / ACCESSWIRE / October 9, 2020 / The following statement is being issued by Levi & Korsinsky, LLP:
Oct 09, 2020 10:44 am ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of MYOK, MOBL, WPX, and STND Mergers
Rigrodsky & Long, P.A. announces that it is investigating: MyoKardia, Inc. (NASDAQ GS: MYOK) regarding possible breaches of fiduciary duties and other violations of law related to MyoKardia’s agreement to be acquired by Bristol-Myers Squibb...
Oct 07, 2020 01:45 pm ET
MERGER ALERT – ARA, MYOK, and AMAG: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
NEW YORK, NY / ACCESSWIRE / October 7, 2020 / The following statement is being issued by Levi & Korsinsky, LLP:
Oct 05, 2020 09:00 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of MyoKardia, Inc. Buyout
Rigrodsky & Long, P.A. announces that it is investigating MyoKardia, Inc. (“MyoKardia”) (NASDAQ GS: MYOK) regarding possible breaches of fiduciary duties and other violations of law related to MyoKardia’s agreement to be acquired by Bristol-Myers...
Oct 05, 2020 03:17 pm ET
MyoKardia Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of MyoKardia, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – MYOK
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of MyoKardia, Inc. (NASDAQ: MYOK) to Bristol-Myers Squibb Company for $225.50 per share in cash is fair to MyoKardia shareholders. On behalf of MyoKardia shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Oct 05, 2020 02:57 pm ET
MYOKARDIA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of MYOK and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of MyoKardia, Inc. (NASDAQ: MYOK) breached their fiduciary duties or violated the federal securities laws...
Oct 05, 2020 06:30 am ET
Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash
Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (Nasdaq: MYOK) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire MyoKardia for $13.1 billion, or $225.00 per share in cash. The transaction was unanimously approved by both the Bristol Myers Squibb and MyoKardia Boards of Directors and is anticipated to clos
Sep 09, 2020 08:00 am ET
MyoKardia Doses First Patient in Phase 2 Clinical Trial of Danicamtiv in Genetic Dilated Cardiomyopathy
MyoKardia, Inc. (Nasdaq: MYOK) today announced that the first patient has been dosed in the company’s Phase 2 clinical trial of danicamtiv (formerly MYK-491) in people with primary dilated cardiomyopathy (DCM) thought to be caused by genetic...
Sep 02, 2020 08:00 am ET
MyoKardia to Participate in September Investor Conferences
MyoKardia, Inc. (Nasdaq: MYOK) today announced its participation in the following upcoming investor conferences: Citi’s 15th Annual BioPharma Virtual Conference on Wednesday, September 9, 2020. Taylor Harris, Chief Financial Officer, will...
Aug 29, 2020 09:30 am ET
MyoKardia Presents Results from Phase 3 EXPLORER-HCM Clinical Trial of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
MyoKardia, Inc. (Nasdaq: MYOK) announced today that 30-week results from its pivotal Phase 3 EXPLORER-HCM clinical trial of mavacamten for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy (HCM) were presented during a live Hot...
Aug 11, 2020 07:35 am ET
MyoKardia and LianBio Form Strategic Partnership to Develop and Commercialize Mavacamten Together in Greater China
MyoKardia, Inc. (Nasdaq: MYOK) and LianBio announced today that they have entered into a strategic collaboration to develop and commercialize mavacamten in China and other Asian territories. Mavacamten is MyoKardia’s lead therapeutic candidate...
Aug 10, 2020 04:05 pm ET
Data from EXPLORER-HCM Study Selected for Virtual Late-Breaker Presentation at the European Society of Cardiology Congress 2020
MyoKardia, Inc. (Nasdaq: MYOK) today announced that the company will present 38-week data from its pivotal Phase 3 EXPLORER-HCM clinical trial during a late-breaker session at the upcoming European Society of Cardiology Congress 2020 (ESC Congress...
Aug 05, 2020 04:05 pm ET
MyoKardia to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference
MyoKardia, Inc. (Nasdaq: MYOK) today announced that Jake Bauer, Chief Business Officer, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020 at 3:30 p.m. ET. A webcast of the presentation will be...
Aug 04, 2020 04:05 pm ET
MyoKardia Reports Second Quarter 2020 Financial Results
MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the second quarter ended June 30, 2020. “The second quarter of 2020 was one of incredible progress across our R&D pipeline, including the exciting new data from our danicamtiv...
Aug 03, 2020 08:30 am ET
MyoKardia Doses First Patient in Phase 3 VALOR-HCM Trial of Mavacamten
MyoKardia, Inc. (Nasdaq: MYOK) announced that the first patient has been dosed in the Phase 3 VALOR-HCM clinical trial.  VALOR-HCM will enroll individuals with obstructive hypertrophic cardiomyopathy (HCM) who have been referred for septal...
Jul 28, 2020 08:00 am ET
MyoKardia to Report Second Quarter 2020 Financial Results on Tuesday, August 4, 2020
MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will report second quarter financial and operating results on Tuesday, August 4, 2020. Management will host a conference call and live audio webcast to discuss these results and provide a...
Jul 23, 2020 04:05 pm ET
MyoKardia Announces Receipt of Breakthrough Therapy Designation from FDA for Mavacamten for the Treatment of Symptomatic, Obstructive Hypertrophic Cardiomyopathy
MyoKardia, Inc. (Nasdaq: MYOK) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to mavacamten, a novel, oral, allosteric modulator of cardiac myosin, for the treatment of symptomatic,...
Jul 21, 2020 07:30 am ET
MyoKardia and Fulcrum Therapeutics Announce Multi-Target Collaboration to Discover Novel Targeted Therapies for Genetic Cardiomyopathies
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases and Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage...
Jul 21, 2020 07:30 am ET
MyoKardia and Fulcrum Therapeutics Announce Multi-Target Collaboration to Discover Novel Targeted Therapies for Genetic Cardiomyopathies
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases and Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage...
Jul 06, 2020 08:00 am ET
MyoKardia Announces Appointment of Denelle J. Waynick as General Counsel and Corporate Secretary
MyoKardia, Inc. (Nasdaq: MYOK) today announced the appointment of Denelle Waynick as General Counsel and Corporate Secretary. Ms. Waynick joins MyoKardia from UCB, Inc., bringing more than 25 years of domestic and international legal and business...
Jun 22, 2020 08:00 am ET
MyoKardia Announces Positive Data from Phase 2a Clinical Trial of Danicamtiv Presented at ESC’s HFA Discoveries with Simultaneous Publication in European Journal of Heart Failure
MyoKardia, Inc. (Nasdaq: MYOK) today announced the presentation and publication of positive data from the company’s Phase 2a clinical trial of danicamtiv (formerly MYK-491) along with nonclinical data elucidating danicamtiv’s novel mechanism of...
Jun 19, 2020 08:30 am ET
MyoKardia Announces Danicamtiv Data Presentation at the European Society of Cardiology’s Virtual Heart Failure Association Discoveries
MyoKardia, Inc. (Nasdaq: MYOK) today announced that data from the company’s Phase 2a multiple-ascending dose study of danicamtiv (formerly MYK-491) in patients with chronic heart failure with reduced ejection fraction (HFrEF) will be presented in a...
Jun 16, 2020 08:00 am ET
MyoKardia to Present at Virtual BMO 2020 Prescriptions for Success Healthcare Conference
MyoKardia, Inc. (Nasdaq: MYOK) today announced that Tassos Gianakakos, Chief Executive Officer, will participate in a fireside chat at the virtual BMO 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23rd, 2020 at 10:30 a.m....
May 12, 2020 09:34 pm ET
MyoKardia Announces Pricing of Public Offering of Common Stock
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases, today announced the pricing of an underwritten public offering of...
May 11, 2020 04:02 pm ET
MyoKardia Announces Proposed Public Offering of Common Stock
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases, today announced that it has commenced a proposed underwritten public...
May 11, 2020 07:30 am ET
MyoKardia Announces Primary and All Secondary Endpoints Met in Phase 3 EXPLORER Clinical Trial of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
MyoKardia, Inc. (Nasdaq: MYOK) today announced positive topline data from the company’s Phase 3 pivotal EXPLORER-HCM clinical trial of mavacamten for the treatment of patients with symptomatic, obstructive hypertrophic cardiomyopathy (HCM)...
May 06, 2020 04:05 pm ET
MyoKardia Reports First Quarter 2020 Financial Results
MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the first quarter ended March 31, 2020. “Our team has continued to drive toward our mission, despite the extraordinary personal and professional disruptions introduced by the...
Mar 30, 2020 10:30 am ET
MyoKardia Announces Mavacamten Treatment Well Tolerated and Significantly Reduced Biomarkers of Cardiac Injury and Wall Stress in Non-Obstructive Hypertrophic Cardiomyopathy Patients
MyoKardia, Inc. (Nasdaq: MYOK) today announced results from the dose-ranging MAVERICK-HCM Phase 2 clinical trial of mavacamten for the treatment of non-obstructive hypertrophic cardiomyopathy (HCM). Data were presented during a late-breaker session...
Mar 26, 2020 08:30 am ET
MyoKardia Provides Clinical Trial Update in the Context of the COVID-19 Pandemic
MyoKardia, Inc. (Nasdaq: MYOK) today provided an update to the status of its clinical programs in the context of the COVID-19 (coronavirus) pandemic given the impact of the pandemic on the global healthcare system’s present ability to support the...
Mar 19, 2020 04:45 pm ET
Data from MAVERICK-HCM Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy Selected for Virtual Late-Breaker Presentation at the American College of Cardiology’s 69th Annual Scientific
MyoKardia, Inc. (Nasdaq: MYOK) today announced that the company will be presenting data from its Phase 2 MAVERICK-HCM clinical trial during a late-breaker session at the upcoming American College of Cardiology’s 69th Annual Scientific Session...
Feb 27, 2020 04:05 pm ET
MyoKardia Reports Fourth Quarter and Full Year 2019 Financial Results
MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the fourth quarter and full year ended December 31, 2019. “MyoKardia achieved significant progress in 2019, advancing our pipeline and regaining global rights to our entire...
Feb 24, 2020 08:00 am ET
MyoKardia to Present at 40th Annual Cowen Health Care Conference
MyoKardia, Inc. (Nasdaq: MYOK), today announced that Taylor Harris, Chief Financial Officer, will present at the 40th Annual Cowen Health Care Conference on Monday, March 2nd 2020 at 1:30 p.m. EST in Boston. A webcast of the presentation will be...
Feb 20, 2020 08:00 am ET
MyoKardia to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020
MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will report fourth quarter and full year 2019 financial and operating results on Thursday, February 27, 2020. Management will host a conference call and live audio webcast to discuss these...
Jan 06, 2020 08:00 am ET
MyoKardia to Present at 38th Annual J.P. Morgan Healthcare Conference
MyoKardia, Inc. (Nasdaq: MYOK), today announced that Tassos Gianakakos, Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13th, 2020 at 8:30 a.m. PT (11:30 a.m. ET) in San Francisco. A...
Nov 27, 2019 08:00 am ET
MyoKardia to Present at Evercore ISI 2nd Annual HealthCONx Conference
MyoKardia, Inc. (Nasdaq: MYOK), today announced that Tassos Gianakakos, Chief Executive Officer, will participate in a fireside chat at the Evercore ISI 2nd  Annual HealthCONx Conference on Wednesday, December 4th, 2019, at 10:15 a.m. ET in Boston,...
Nov 11, 2019 07:30 am ET
MyoKardia Announces 48-week Data from PIONEER-OLE Study of Mavacamten
MyoKardia, Inc. (Nasdaq: MYOK) today announced new data from the company’s PIONEER open-label extension (OLE) study of mavacamten for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy (HCM). Data for twelve patients at 48 weeks...
Nov 11, 2019 07:30 am ET
MyoKardia Announces Positive Topline Data from its Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten
MyoKardia, Inc. (Nasdaq: MYOK), today announced topline data from MAVERICK-HCM, the company’s Phase 2 clinical trial of mavacamten in patients with non-obstructive hypertrophic cardiomyopathy (HCM).  The study achieved its primary objective of...
Nov 06, 2019 04:05 pm ET
MyoKardia to Present at Credit Suisse 28th Annual Healthcare Conference
MyoKardia, Inc. (Nasdaq: MYOK), today announced that Tassos Gianakakos, Chief Executive Officer, will participate in a fireside chat at the Credit Suisse 28th Annual Healthcare Conference on Wednesday, November 13th, 2019, at 9:45 a.m. MT (11:45...
Nov 04, 2019 04:44 pm ET
MyoKardia Reports Third Quarter 2019 Financial Results
MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the quarter ended September 30, 2019. “As we look across the milestones recently achieved and those just ahead, we see steady progress on our near- and long-term corporate...
Nov 04, 2019 08:30 am ET
MyoKardia Announces Abstracts Selected for Presentation at the American Heart Association Scientific Sessions 2019
MyoKardia, Inc. (Nasdaq: MYOK), today announced the presentation of several abstracts at the upcoming American Heart Association (AHA) Scientific Sessions taking place November 16 – November 18, 2019 in Philadelphia, Pennsylvania. The abstracts...
Oct 28, 2019 08:30 am ET
MyoKardia Announces Positive MYK-491 Data; Advancing Program into Targeted Genetic Dilated Cardiomyopathy Population
MyoKardia, Inc. (Nasdaq: MYOK), today announced positive interim data from the company’s Phase 2a clinical trial of MYK-491 and will advance MYK-491 into a Phase 2 study in patients with genetic dilated cardiomyopathy (DCM). MYK-491 is MyoKardia’s...
Sep 26, 2019 04:05 pm ET
MyoKardia to Present at 2019 Cantor Global Healthcare Conference
MyoKardia, Inc. (Nasdaq: MYOK), today announced that Taylor Harris, Chief Financial Officer, will participate in a fireside chat at the 2019 Cantor Global Healthcare Conference on Thursday, October 3, 2019, at 4:10 p.m. ET in New York, NY. A...
Sep 10, 2019 08:44 am ET
MyoKardia to Evaluate Mavacamten as an Alternative to Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Patients
MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will study mavacamten as a therapeutic alternative to septal reduction therapy (SRT). The study will be conducted at leading HCM centers that regularly perform surgical myectomy or alcohol...
Aug 31, 2019 05:00 am ET
MyoKardia Presents 36-week Data from PIONEER-OLE Study of Mavacamten at the European Society of Cardiology Congress 2019
MyoKardia, Inc. (Nasdaq: MYOK) today presented positive data from the company’s PIONEER open-label extension (OLE) study of mavacamten for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy (HCM) at the European Society of...
Aug 28, 2019 04:05 pm ET
MyoKardia to Participate in September Investor Conferences
MyoKardia, Inc. (Nasdaq: MYOK), today announced its participation in the following upcoming investor conferences: Citi 14th Annual Biotech Conference in Boston, MA on Wednesday, September 4, 2019.2019 Wells Fargo Healthcare Conference in Boston,...
Aug 26, 2019 08:30 am ET
MyoKardia Announces Abstracts Selected for Presentation at the European Society of Cardiology Congress 2019
MyoKardia, Inc. (Nasdaq: MYOK) today announced the presentation of three abstracts at the upcoming European Society of Cardiology (ESC) Congress taking place August 31 – September 4, 2019 in Paris, France. Among the highlights of the data being...
Aug 21, 2019 08:30 am ET
MyoKardia Begins Dosing in Phase 1 Clinical Study of MYK-224 for Hypertrophic Cardiomyopathy
MyoKardia, Inc. (Nasdaq: MYOK) today announced that it has dosed the first subjects in a Phase 1 clinical study of MYK-224, a small molecule candidate being developed for the treatment of hypertrophic cardiomyopathy (HCM). HCM is a progressive...
Aug 15, 2019 08:30 am ET
MyoKardia Launches 2nd Annual MyoSeeds™ Research Grants Program to Advance Independent Research in Heart Disease
MyoKardia, Inc. today announced the launch of the 2nd Annual MyoSeeds™ Research Grants Program, an initiative to support original, independent research in the biology and underlying mechanisms of cardiomyopathies and precision heart disease...
Aug 07, 2019 04:05 pm ET
MyoKardia Reports Second Quarter 2019 Financial Results
MyoKardia, Inc. (Nasdaq: MYOK) today reported financial results for the second quarter ended June 30, 2019. “We are now less than a year away from potentially game-changing pivotal data from our EXPLORER-HCM clinical trial of mavacamten in...
Aug 07, 2019 08:00 am ET
MyoKardia to Present at 2019 Wedbush PacGrow Healthcare Conference
MyoKardia, Inc. (Nasdaq: MYOK), today announced that Taylor Harris, Chief Financial Officer, will present at the 2019 Wedbush PacGrow Healthcare Conference on Wednesday, August 14th, 2019, at 10:55 a.m. ET in New York, NY. A webcast of the...
Jul 31, 2019 04:05 pm ET
MyoKardia to Report Second Quarter 2019 Financial Results on Wednesday, August 7, 2019
MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will report second quarter 2019 financial and operating results on Wednesday, August 7, 2019. Management will host a conference call and live audio webcast to discuss these results and provide...
Jul 18, 2019 08:30 am ET
MyoKardia Announces HCM Program Updates: Accelerates Timing for Mavacamten Topline Phase 3 Data; Re-acquires U.S. Royalty Rights to HCM Programs from Sanofi
MyoKardia, Inc. (Nasdaq: MYOK) today announced updates related to its hypertrophic cardiomyopathy (HCM) treatment portfolio, including lead therapeutic candidate, mavacamten.  Patient screening has closed for the Phase 3 EXPLORER-HCM...
Jun 24, 2019 08:30 am ET
MyoKardia Publishes Data in Nature Digital Medicine Showing Potential of Wrist-Worn Biosensor to Screen for Hypertrophic Cardiomyopathy
MyoKardia, Inc. (Nasdaq: MYOK) today announced the publication of an article titled, “Machine Learning Detection of Obstructive Hypertrophic Cardiomyopathy (oHCM) Using a Wearable Biosensor,” in the Nature Partner Journal, Digital Medicine. This...
Jun 18, 2019 04:05 pm ET
MyoKardia to Present at 2019 BMO Prescriptions for Success Healthcare Conference
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced that Jake Bauer, Chief Business Officer, will participate in a...
May 28, 2019 08:30 am ET
MyoKardia Presents Results from Phase 1a Clinical Trial of MYK-491 at the European Society of Cardiology Heart Failure Congress in Athens, Greece
MyoKardia, Inc., (Nasdaq: MYOK), presented data today at the European Society of Cardiology Heart Failure Congress from its Phase 1a single-ascending dose study of MYK-491 in healthy volunteers. MYK-491 is MyoKardia’s most advanced activator...
May 09, 2019 04:05 pm ET
MyoKardia Reports First Quarter 2019 Financial Results
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today reported financial results for the quarter ended March 31, 2019....
May 08, 2019 04:10 pm ET
MyoKardia to Present at Bank of America Merrill Lynch 2019 Health Care Conference
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer, will...
May 07, 2019 04:10 pm ET
MyoKardia Announces Inaugural MyoSeeds™ Research Grants Program Awardees
MyoKardia, a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of serious cardiovascular diseases, today announced the award of $750,000 divided among three innovative research projects through the first cycle...
May 02, 2019 08:00 am ET
MyoKardia to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced that it will report first quarter 2019 financial and operating...
Apr 30, 2019 08:30 am ET
Clinical Trial Results from MyoKardia’s Phase 2 PIONEER-HCM Study of Mavacamten Published in the Annals of Internal Medicine
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced the publication of results from the company’s Phase 2...
Mar 27, 2019 07:30 am ET
Detailed Research: Economic Perspectives on TIER REIT, MyoKardia, Radian Group, Packaging Corporation of America, Air Products and Chemicals, and ProAssurance — What Drives Growth in Today's Competiti
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of TIER REIT, Inc. (NYSE:TIER), MyoKardia, Inc. (NASDAQ:MYOK), Radian...
Mar 26, 2019 06:45 pm ET
MyoKardia Announces Pricing of Public Offering of Common Stock
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced the pricing of an underwritten public offering of 4,925,000...
Mar 25, 2019 04:01 pm ET
MyoKardia Announces Proposed Public Offering of Common Stock
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced that it has commenced a proposed underwritten public offering...
Mar 06, 2019 08:00 am ET
MyoKardia to Present at Cowen & Co. 39th Annual Health Care Conference
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of serious cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer, will present at the...
Mar 04, 2019 08:02 am ET
MyoKardia Announces Positive Six-Month Safety and Efficacy Data from PIONEER-OLE Study of Mavacamten for the Treatment of Symptomatic, Obstructive HCM
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced positive 12- and 24-week safety, efficacy and biomarker data...
Feb 28, 2019 08:30 am ET
MyoKardia Reports Fourth Quarter and Full Year 2018 Financial Results
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today reported financial results for the fourth quarter and full year ended...
Feb 04, 2019 08:15 am ET
Market Trends Toward New Normal in Duke Energy, VICI Properties, MyoKardia, FLIR, TIER REIT, and ChannelAdvisor — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Duke Energy Corporation (NYSE:DUK), VICI Properties Inc. (NYSE:VICI),...
Jan 23, 2019 08:30 am ET
MyoKardia Appoints William Fairey as Chief Commercial Officer
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the appointment of William C. Fairey as Chief Commercial...
Jan 03, 2019 08:00 am ET
MyoKardia to Present at 37th Annual J.P. Morgan Healthcare Conference
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer, will present at the 37th Annual...
Jan 02, 2019 08:00 am ET
MyoKardia Regains Global Rights to Mavacamten and MYK-491 Programs from Sanofi
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced it has regained worldwide rights to all programs covered under its license and...
Dec 11, 2018 08:30 am ET
MyoKardia Reports Positive Data from Phase 1b Single-Ascending Dose Clinical Trial of MYK-491 in Dilated Cardiomyopathy and Systolic Heart Failure Patients
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced topline results from the Phase 1b single-ascending dose study of MYK-491....
Dec 05, 2018 04:01 pm ET
MyoKardia to Present at the BMO 2018 Prescriptions for Success Healthcare Conference
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that Taylor Harris, Chief Financial Officer, will present at the BMO 2018...
Nov 28, 2018 08:55 am ET
Consolidated Research: 2018 Summary Expectations for MyoKardia, Bristow Group, The Chefs' Warehouse, Catabasis Pharmaceuticals, Casa, and EP Energy — Fundamental Analysis, Key Performance Indications
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of MyoKardia, Inc. (NASDAQ:MYOK), Bristow Group Inc (NYSE:BRS), The Chefs'...
Nov 12, 2018 07:30 am ET
MyoKardia Presents Preclinical Evidence of Mavacamten’s Novel Effect on Diastolic Compliance at the 2018 American Heart Association Scientific Sessions
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, presented preclinical data at the American Heart Association (AHA) Scientific Sessions 2018 that...
Nov 07, 2018 04:30 pm ET
MyoKardia Reports Third Quarter 2018 Financial Results
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today reported financial results for the quarter ended September 30, 2018.  “MyoKardia continues...
Nov 07, 2018 08:01 am ET
MyoKardia to Present at the Credit Suisse 27th Annual Healthcare Conference
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced today announced that Jake Bauer, Chief Business Officer, will provide a corporate...
Nov 05, 2018 08:00 am ET
MyoKardia Announces Twelve Abstracts Accepted for Presentation During the 2018 American Heart Association Scientific Sessions
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced the presentation of twelve abstracts at the upcoming American Heart Association...
Nov 05, 2018 08:00 am ET
MyoKardia to Present Clinical Evidence of Mavacamten’s Effect on Diastolic Function at 2018 American Heart Association Scientific Sessions
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced new clinical data describing mavacamten’s effect on diastolic function will be...
Oct 30, 2018 07:30 am ET
MyoKardia Shares Data from Ongoing Clinical Programs and Details Three New Research Programs at 2018 R&D Day
MyoKardia, Inc., (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, announced a comprehensive update on its clinical-stage and emerging pipeline today at its 2018...
Oct 25, 2018 12:00 am ET
MyoKardia Announces Initiative to Create Hypertrophic Cardiomyopathy Patient Community in Collaboration with 23andMe
MyoKardia, Inc., (Nasdaq: MYOK), a clinical stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that it has entered into a collaboration with 23andMe to advance research for...
Oct 24, 2018 04:30 pm ET
MyoKardia Doses First Patient in MAVA Long-Term Extension Study of Mavacamten for Hypertrophic Cardiomyopathy
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that patient dosing has begun in the MAVA Long-Term Extension (MAVA-LTE) clinical...
Oct 22, 2018 08:30 am ET
MyoKardia to Host R&D Day on October 30, 2018
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that it will host a Research and Development (R) Day for analysts and investors...
Oct 19, 2018 08:30 am ET
Recent Analysis Shows Vipshop, MyoKardia, HudBay Minerals, Nordic American Tankers, Yum China, and TIM Participacoes S.A. Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Vipshop Holdings Limited (NYSE:VIPS), MyoKardia, Inc. (NASDAQ:MYOK),...
Sep 24, 2018 08:01 am ET
MyoKardia to Present at the 2018 Cantor Global Healthcare Conference
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer, will present at the 2018 Cantor...
Aug 29, 2018 04:01 pm ET
MyoKardia to Present at Two Upcoming Investor Conferences in September
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that senior company management will be participating in the following upcoming...
Aug 23, 2018 08:00 am ET
New Insights on Disease Burden for Hypertrophic Cardiomyopathy Patients Published in Circulation
The Sarcomeric Human Cardiomyopathy Registry (SHaRe) and MyoKardia, Inc. (Nasdaq: MYOK) announced today the publication of results from a multicenter, international, longitudinal study of data from nearly 4,600 patients with hypertrophic...
Aug 21, 2018 07:30 am ET
Analysis: Positioning to Benefit within Alamos Gold, Nomad Foods, MyoKardia, Mesoblast, Core-Mark Holding, and Jounce Therapeutics — Research Highlights Growth, Revenue, and Consolidated Results
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Alamos Gold Inc. (NYSE:AGI), Nomad Foods Limited (NYSE:NOMD), MyoKardia,...
Aug 08, 2018 04:02 pm ET
MyoKardia Reports Second Quarter 2018 Financial Results
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today reported financial results for the quarter ended June 30, 2018.  “This quarter saw...
Aug 07, 2018 04:01 pm ET
MyoKardia to Present at the 2018 Wedbush Pacgrow Healthcare Conference
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer,  will...
Aug 01, 2018 04:30 pm ET
MyoKardia to Report Second Quarter 2018 Financial Results on Wednesday, August 8, 2018
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it will report second quarter 2018 financial and...
Jun 26, 2018 08:30 am ET
MyoKardia Doses First Patient in Pivotal Phase 3 EXPLORER-HCM Trial of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that the first patient has been dosed in the company’s Phase...
Jun 06, 2018 08:30 am ET
Analysis: Positioning to Benefit within Willis Towers Watson Public, MyoKardia, Texas Capital Bancshares, uniQure N.V, Retail Opportunity Investments, and GDS Holdings Limited — Research Highlights Gr
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Willis Towers Watson Public Limited Company (NASDAQ:WLTW), MyoKardia, Inc....
May 22, 2018 08:05 pm ET
MyoKardia Announces Pricing of Public Offering of Common Stock
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the pricing of an underwritten public offering of 3,750,000...
May 21, 2018 04:01 pm ET
MyoKardia Announces Proposed Public Offering of Common Stock
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it has commenced a proposed underwritten public offering...
May 21, 2018 07:30 am ET
MyoKardia Announces Design of Phase 3 EXPLORER-HCM Study Evaluating Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the design of its pivotal Phase 3 EXPLORER-HCM clinical trial...
May 10, 2018 04:30 pm ET
MyoKardia to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer,  will...
May 10, 2018 08:30 am ET
MyoKardia Doses First Patient in PIONEER Open-Label Extension Study of Mavacamten for Symptomatic, Obstructive Hypertrophic Cardiomyopathy
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the start of the PIONEER open-label extension (OLE) study of...
May 08, 2018 04:01 pm ET
MyoKardia Reports First Quarter 2018 Financial Results
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today reported financial results for the quarter ended March 31, 2018....
May 03, 2018 04:01 pm ET
MyoKardia to Report First Quarter 2018 Financial Results on Tuesday, May 8, 2018
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it will report first quarter 2018 financial and...
Apr 09, 2018 08:10 am ET
New Research Coverage Highlights Alliance Resource Partners, MyoKardia, Pan American Silver, Stitch Fix, Codexis, and Chemical Financial — Consolidated Revenues, Company Growth, and Expectations for 2
NEW YORK, April 09, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Alliance Resource Partners, L.P. (NASDAQ:ARLP), MyoKardia,...
Apr 04, 2018 08:30 am ET
MyoKardia Announces Appointment of Taylor C. Harris as Chief Financial Officer
SOUTH SAN FRANCISCO, Calif., April 04, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the appointment of Taylor C. Harris as...
Mar 16, 2018 08:15 am ET
Recent Analysis Shows Clementia Pharmaceuticals, MyoKardia, Landec, Sapiens International Corporation N.V, AppFolio, and China Biologic Products Market Influences — Renewed Outlook, Key Drivers of Gro
NEW YORK, March 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), MyoKardia, Inc....
Mar 08, 2018 04:03 pm ET
MyoKardia Reports Fourth Quarter and Full Year 2017 Financial Results
Announced Achievement of Primary Endpoint and Additional Key Data from Low-Dose Mavacamten Cohort of PIONEER-HCM Phase 2 Study in Symptomatic, Obstructive Hypertrophic Cardiomyopathy
Mar 06, 2018 08:00 am ET
MyoKardia to Present at the Cowen and Company 38th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer,  will present at...
Mar 01, 2018 04:30 pm ET
MyoKardia to Report Fourth Quarter and Full Year 2017 Financial Results on Thursday, March 8, 2018
SOUTH SAN FRANCISCO, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it will report fourth quarter and...
Feb 14, 2018 04:30 pm ET
MyoKardia to Present at the RBC Capital Markets’ 2018 Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that senior management will participate in a fireside chat...
Feb 14, 2018 08:30 am ET
MyoKardia Begins Patient Dosing in Phase 1b Clinical Study of MYK-491 in Dilated Cardiomyopathy Patients
Topline Results from First-in-Human Phase 1 Study of MYK-491 in Healthy Volunteers Demonstrated Tolerability and Increased Contractility
Jan 19, 2018 08:30 am ET
MyoKardia Announces Appointment of Cynthia Ladd as General Counsel
SOUTH SAN FRANCISCO, Calif., Jan. 19, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the expansion of its executive committee with...
Jan 03, 2018 04:30 pm ET
MyoKardia to Present at 36th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer, is scheduled...
Nov 15, 2017 08:00 am ET
Preclinical Studies with MyoKardia’s Mavacamten Demonstrate Evidence of Reduced Contractility and Improved Left Ventricular Compliance
SOUTH SAN FRANCISCO, Calif., Nov. 15, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, presented data that further elucidates the mechanism of action...
Nov 13, 2017 07:15 pm ET
MyoKardia Presents Data from Study of Machine Learning Algorithm Intended to Identify Obstructive Hypertrophic Cardiomyopathy Using a Wearable Biosensor
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, presented results from testing a novel machine learning algorithm intended to identify patients with obstructive hypertrophic cardiomyopathy (oHCM) during a late-breaker session at the American Heart Association (AHA) Scientific Sessions.  ...
Nov 13, 2017 07:15 pm ET
MyoKardia Presents Data from Study of Machine Learning Algorithm Intended to Identify Obstructive Hypertrophic Cardiomyopathy Using a Wearable Biosensor
Digital Health Data from Substudy of PIONEER-HCM Presented in Late-Breaker at American Heart Association Scientific Sessions
Nov 02, 2017 04:02 pm ET
MyoKardia Reports Third Quarter 2017 Financial Results and Operational Progress
Received FDA Feedback for Mavacamten Registration Program in Symptomatic, Obstructive Hypertrophic Cardiomyopathy
Nov 01, 2017 08:00 am ET
MyoKardia Announces Presentations at 2017 American Heart Association Scientific Sessions
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that company research will be presented...
Sep 18, 2017 12:45 pm ET
MyoKardia Presents Additional Positive Data from Phase 2 PIONEER-HCM Study of Mavacamten (Formerly MYK-461) at the Heart Failure Society of America’s 21st Annual Scientific Meeting
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK) (“MyoKardia” or the “Company”), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study of mavacamten in symptomatic, obstructive hypertrophic cardiomyopathy (oHCM) patients were presented at the Heart Failure Society of America (HFSA)’s 21st Annual Scientific Meeting in Dallas, TX....
Aug 07, 2017 04:01 pm ET
MyoKardia Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK) (“MyoKardia” or the “Company”), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it has commenced a proposed underwritten public offering of 3,500,000 shares of its common stock. All shares of common stock will be offered by MyoKardia. In addition, MyoKardia expects to grant the underwriters a 30-day option to purchase an additional 525,000 shares of common stock at the public offering pric...
Aug 07, 2017 07:19 am ET
MyoKardia Reports Second Quarter 2017 Financial Results and Operational Progress
Positive Topline Results in First Patient Cohort of Phase 2 PIONEER-HCM Study...
Apr 18, 2017 08:30 am ET
MyoKardia Appoints David Meeker, M.D., to Board of Directors
SOUTH SAN FRANCISCO, Calif., April 18, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the appointment of David Meeker, M.D., to the Company’s board of directors....
Dec 01, 2016 08:00 am ET
MyoKardia Announces Appointment of Marc Semigran, M.D., as Chief Medical Officer
Former Medical Director of the Heart Failure and Cardiac Transplant Program at Massachusetts General Hospital to Lead Clinical Development...
Nov 07, 2016 08:00 am ET
MyoKardia Reports Progress on Clinical Programs and Third Quarter 2016 Financial Results
Dosing in Phase 2 PIONEER-HCM trial of MYK-461 in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Under Way; Pathway to Registration Outlined             MYK-491 Dilated Cardiomyopathy Candidate Set to Enter Clinic in First Half of 2017...
Nov 02, 2016 08:00 am ET
MyoKardia Announces Dosing of First Patient in Phase 2 PIONEER-HCM Study of MYK-461 in Symptomatic, Obstructive Hypertrophic Cardiomyopathy
         Pilot Study Designed to Enable Progression to Larger Phase 2 Trial to Finalize Dosing and Endpoints Prior to Single Pivotal Study...
Oct 31, 2016 08:00 am ET
MyoKardia to Present at Two Upcoming Investor Conferences in November 
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Tassos Gianakakos, chief executive officer, will participate in two upcoming investor conferences in November. Following are details for each presentation:...
Oct 03, 2016 04:30 pm ET
MyoKardia Announces Closing of Public Offering of Common Stock Including Full Exercise of Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., Oct. 03, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the closing of its previously announced underwritten public offering of 4,370,000 shares of common stock, at the public offering price of $15.00 per share, which included 570,000 shares sold pursuant to the full exercise by the underwriters of their option to purchase additional shares. All of the shares in the offering were offered by MyoKardi...
Sep 27, 2016 06:47 pm ET
MyoKardia Announces Pricing of Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the pricing of an underwritten public offering of 3,800,000 shares of its common stock at a public offering price of $15.00 per share, before underwriting discounts. In addition, the underwriters have a 30-day option to purchase up to an additional 570,000 shares of common stock on the same terms and conditions....
Sep 26, 2016 04:48 pm ET
MyoKardia Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it has commenced an underwritten public offering of 3,800,000 shares of its common stock. All shares of common stock will be offered by MyoKardia. In addition, MyoKardia expects to grant the underwriters a 30-day option to purchase up to an additional 570,000 shares of common stock at the public offering price, less the underwriting discoun...
Sep 21, 2016 07:00 am ET
Sep 14, 2016 08:45 am ET
MyoKardia to Host R&D Day on September 21
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, will host a Research and Development (R&D) Day for analysts and investors on Sept. 21, 2016, at 8:30 a.m. ET in New York City....
Sep 01, 2016 04:30 pm ET
MyoKardia to Present at 2016 Wells Fargo Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Tassos Gianakakos, chief executive officer, will present at the 2016 Wells Fargo Healthcare Conference on Thursday, September 8, 2016, at 2:55 PM Eastern Time. The conference is being held at the Westin Waterfront Hotel in Boston....
Aug 10, 2016 08:30 am ET
MyoKardia to Present at the 2016 Wedbush PacGrow Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 10, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that members of the Company management team will present at the 2016 Wedbush PacGrow Healthcare Conference on Tuesday, August 16, 2016 at 2:30 PM Eastern Time. The conference is being held at Le Parker Meridien Hotel in New York City....
Aug 09, 2016 08:30 am ET
MyoKardia Reports Second Quarter 2016 Financial Results and Continued Progress on Clinical Programs
MYK-461 Phase 2 PIONEER-HCM Study to Initiate in Second Half of 2016...
Jul 14, 2016 08:30 am ET
SHaRe Registry Data Published in PNAS Demonstrate the Power of Combining Clinical, Genetic and Structural Data to Gain Insight into Hypertrophic Cardiomyopathy
SOUTH SAN FRANCISCO, Calif., July 14, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the publication of an article in the Proceedings of the National Academy of Sciences of the United States of America. The article is the first to examine data from SHaRe, or the Sarcomeric Human Cardiomyopathy Registry, and demonstrates the power of combining clinical, genetic and structural data to gain insight into hypertrophic cardiomyopathy (...
Jul 11, 2016 04:02 pm ET
MyoKardia Announces Topline Clinical Data Supporting Advancement of MYK-461 to Phase 2 PIONEER-HCM Study in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients
MYK-461 Data Suggest Favorable Safety Profile Up to 28 Days Dosing in Healthy Volunteers and Reduction in Excess Cardiac Contractility in All HCM Patients Studied...
May 16, 2016 07:30 am ET
MyoKardia to Present at 2016 UBS Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 16, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that members of the Company management team are scheduled to present at the 2016 UBS Global Healthcare Conference on Monday, May 23, at 4:00 PM Eastern Time. The conference is being held May 23-25 at the Grand Hyatt New York in Manhattan....
May 12, 2016 07:30 am ET
MyoKardia Reports First Quarter 2016 Financial Results and Operational Progress
SOUTH SAN FRANCISCO, Calif., May 12, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today reported business highlights and financial results for the first quarter ended March 31, 2016....
May 02, 2016 07:30 am ET
MyoKardia Receives Orphan Drug Designation for MYK-461 for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
SOUTH SAN FRANCISCO, Calif., May 02, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted the company Orphan Drug Designation for MYK-461 for treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM), a subset of hypertrophic cardiomyopathy (HCM)....

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.